UTHR
VENTE TOTALE: 249 043 titres (~134 890 812,56 $ US)
- Insiders
- ROTHBLATT MARTINE A, MALCOLM JAN
- Total bought
- —
- Total sold
- $134,890,813
- Last activity
- —
- Last synced
-
2026-07-29 15:28:58
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
UTHR presents exceptional financial fundamentals with a near-pristine balance sheet, ~42% net margins, and strong liquidity (scores 95/85), providing a solid foundation.
The first sentence of the analysis written for UTHR on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 87.9% | 89.2% | 88.9% | 92.4% | 92.7% | |
| Ebit Margin | 54.5% | 55.0% | 57.3% | 51.1% | 40.8% | |
| Ebitda Margin | 57.2% | 57.5% | 59.6% | 53.7% | 43.7% | |
| Operating Profit Margin | 47.7% | 47.9% | 50.9% | 50.6% | 33.0% | |
| Pretax Profit Margin | 53.9% | 53.5% | 54.7% | 49.1% | 35.2% | |
| Continuous Operations Profit Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | |
| Net Profit Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | |
| Bottom Line Profit Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | |
| Current Ratio | 6.605 | 5.248 | 4.414 | 9.849 | 7.608 | |
| Quick Ratio | 6.278 | 5.035 | 4.275 | 9.552 | 7.301 | |
| Solvency Ratio | 1.812 | 1.378 | 0.878 | 0.624 | 0.434 | |
| Cash Ratio | 2.778 | 2.299 | 1.501 | 2.801 | 2.930 | |
| Price To Earnings Ratio | 16.172 | 13.345 | 10.451 | 17.402 | 20.385 | |
| Price To Earnings Growth Ratio | 1.159 | 0.520 | 0.330 | 0.343 | -2.262 | |
| Forward Price To Earnings Growth Ratio | 1.159 | 0.520 | 0.330 | 0.343 | -2.262 | |
| Price To Book Ratio | 3.042 | 2.475 | 1.719 | 2.638 | 2.451 | |
| Price To Sales Ratio | 6.782 | 5.543 | 4.421 | 6.535 | 5.756 | |
| Price To Free Cash Flow Ratio | 20.741 | 14.759 | 13.765 | 19.064 | 20.323 | |
| Price To Operating Cash Flow Ratio | 13.826 | 12.017 | 10.522 | 15.767 | 16.219 | |
| Debt To Assets Ratio | 0.005 | 0.041 | 0.098 | 0.132 | 0.155 | |
| Debt To Equity Ratio | 0.005 | 0.047 | 0.117 | 0.167 | 0.202 | |
| Debt To Capital Ratio | 0.005 | 0.044 | 0.105 | 0.143 | 0.168 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.048 | 0.143 | 0.168 | |
| Financial Leverage Ratio | 1.110 | 1.143 | 1.198 | 1.260 | 1.306 | |
| Working Capital Turnover Ratio | 1.014 | 0.978 | 0.805 | 0.766 | 0.873 | |
| Operating Cash Flow Ratio | 2.785 | 1.798 | 1.216 | 2.338 | 1.959 | |
| Operating Cash Flow Sales Ratio | 0.491 | 0.461 | 0.420 | 0.414 | 0.355 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.667 | 0.814 | 0.764 | 0.827 | 0.798 | |
| Debt Service Coverage Ratio | 73.836 | 3.822 | 2.389 | 25.216 | 33.263 | |
| Interest Coverage Ratio | 77.805 | 32.098 | 19.981 | 30.238 | 29.887 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 4.424 | 2.445 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 41.521 | 4.424 | 1.397 | 1.003 | 0.748 | |
| Capital Expenditure Coverage Ratio | 2.999 | 5.384 | 4.245 | 5.782 | 4.952 | |
| Dividend Paid And Capex Coverage Ratio | 2.999 | 5.384 | 4.245 | 5.782 | 4.952 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 11.031 | 8.795 | 7.054 | 12.008 | 13.039 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 87.9% | ▼-1.3% | ▼-2.3% |
| Ebit Margin | 54.5% | ▼-0.5% | ▲2.8% |
| Ebitda Margin | 57.1% | ▼-0.3% | ▲2.8% |
| Operating Profit Margin | 47.7% | ▼-0.2% | ▲1.7% |
| Pretax Profit Margin | 53.8% | ▲0.4% | ▲4.6% |
| Continuous Operations Profit Margin | 41.9% | ▲0.4% | ▲3.6% |
| Net Profit Margin | 41.9% | ▲0.4% | ▲3.6% |
| Bottom Line Profit Margin | 41.9% | ▲0.4% | ▲3.6% |
| Current Ratio | 6.604 | ▲1.356 | ▼-0.141 |
| Quick Ratio | 6.278 | ▲1.243 | ▼-0.210 |
| Solvency Ratio | 1.812 | ▲0.434 | ▲0.787 |
| Cash Ratio | 2.778 | ▲0.478 | ▲0.316 |
| Price To Earnings Ratio | 16.172 | ▲2.827 | ▲0.621 |
| Price To Earnings Growth Ratio | 1.159 | ▲0.639 | ▲1.141 |
| Forward Price To Earnings Growth Ratio | 1.159 | ▲0.639 | ▲1.141 |
| Price To Book Ratio | 3.042 | ▲0.567 | ▲0.577 |
| Price To Sales Ratio | 6.782 | ▲1.239 | ▲0.975 |
| Price To Free Cash Flow Ratio | 20.741 | ▲5.982 | ▲3.011 |
| Price To Operating Cash Flow Ratio | 13.826 | ▲1.809 | ▲0.156 |
| Debt To Assets Ratio | 0.005 | ▼-0.036 | ▼-0.081 |
| Debt To Equity Ratio | 0.005 | ▼-0.041 | ▼-0.102 |
| Debt To Capital Ratio | 0.005 | ▼-0.039 | ▼-0.088 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.072 |
| Financial Leverage Ratio | 1.111 | ▼-0.032 | ▼-0.093 |
| Working Capital Turnover Ratio | 1.014 | ▲0.036 | ▲0.127 |
| Operating Cash Flow Ratio | 2.785 | ▲0.987 | ▲0.766 |
| Operating Cash Flow Sales Ratio | 0.490 | ▲0.029 | ▲0.062 |
| Free Cash Flow Operating Cash Flow Ratio | 0.667 | ▼-0.148 | ▼-0.107 |
| Debt Service Coverage Ratio | 73.836 | ▲70.014 | ▲46.131 |
| Interest Coverage Ratio | 77.805 | ▲45.707 | ▲39.803 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-4.424 | ▼-1.374 |
| Operating Cash Flow Coverage Ratio | 41.521 | ▲37.098 | ▲31.703 |
| Capital Expenditure Coverage Ratio | 2.999 | ▼-2.384 | ▼-1.673 |
| Dividend Paid And Capex Coverage Ratio | 2.999 | ▼-2.384 | ▼-1.673 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 11.031 | ▲2.236 | ▲0.645 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $21.59B | $15.95B | $10.29B | $12.65B | $9.70B | |
| Enterprise value | $20.07B | $14.55B | $9.78B | $12.49B | $9.61B | |
| EV / Sales | 6.30x | 5.06x | 4.20x | 6.45x | 5.70x | |
| EV / Op. cash flow | 12.85x | 10.96x | 10.00x | 15.57x | 16.06x | |
| EV / Free cash flow | 19.28x | 13.47x | 13.09x | 18.82x | 20.12x | |
| EV / EBITDA | 11.03x | 8.79x | 7.05x | 12.01x | 13.04x | |
| Net debt / EBITDA | -0.83x | -0.84x | -0.37x | -0.15x | -0.13x | |
| Current ratio | 6.61x | 5.25x | 4.41x | 9.85x | 7.61x | |
| Income quality | 1.17x | 1.11x | 0.99x | 1.10x | 1.26x | |
| Graham number | $330 | $291 | $246 | $195 | $145 | |
| Graham net-net | $25 | $58 | $44 | $40 | $20 | |
| Tax burden | 77.9% | 77.7% | 77.3% | 76.5% | 80.1% | |
| Interest burden | 98.9% | 97.3% | 95.6% | 96.1% | 86.5% | |
| Working capital | $3.14B | $3.14B | $2.75B | $3.04B | $2.02B | |
| Invested capital | $4.99B | $4.47B | $3.91B | $3.94B | $2.84B | |
| Return on assets | 16.9% | 16.2% | 13.7% | 12.0% | 9.2% | |
| Operating ROA | 19.9% | 19.0% | 17.9% | 17.5% | 11.4% | |
| Return on tangible assets | 17.2% | 16.5% | 14.0% | 12.1% | 9.3% | |
| Return on equity | 18.8% | 18.5% | 16.5% | 15.2% | 12.0% | |
| Return on invested capital | 16.1% | 15.4% | 13.5% | 13.1% | 9.2% | |
| Return on capital employed | 20.7% | 20.8% | 18.6% | 17.2% | 11.4% | |
| Earnings yield | 6.2% | 7.5% | 9.6% | 5.7% | 4.9% | |
| Free cash flow yield | 4.8% | 6.8% | 7.3% | 5.2% | 4.9% | |
| Capex / Op. cash flow | 33.3% | 18.6% | 23.6% | 17.3% | 20.2% | |
| Capex / Depreciation | 608.1% | 340.0% | 433.1% | 270.6% | 242.1% | |
| Capex / Sales | 16.4% | 8.6% | 9.9% | 7.2% | 7.2% | |
| SG&A / Sales | 23.0% | 22.2% | 20.5% | 25.2% | 27.7% | |
| R&D / Sales | 17.3% | 16.7% | 17.5% | 16.7% | 32.0% | |
| Stock comp / Sales | 4.6% | 5.0% | 1.7% | 5.5% | 8.2% | |
| Intangibles / Total assets | 1.5% | 1.5% | 1.6% | 0.7% | 0.9% | |
| Days sales outstanding | 40d | 35d | 44d | 42d | 43d | |
| Days payables outstanding | 7d | 7d | 8d | 10d | 11d | |
| Operating cycle | 214d | 222d | 202d | 295d | 323d | |
| Cash conversion cycle | 207d | 214d | 194d | 285d | 311d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+35.3%EV / Sales ▲+24.7%EV / EBITDA ▲+25.4%EV / Op. cash flow ▲+1.888Earnings yield ▼-0.013Graham number ▲+38.300
Profitability
Return on equity ▲+0.003Return on assets ▲+0.007Return on invested capital ▲+0.007Return on capital employed ▼-0.001Operating ROA ▲+0.010Income quality ▲+0.059Tax burden ▲+0.002
Efficiency
Days sales outstanding ▲+4.732Days payables outstanding ▼-0.330Operating cycle ▼-7.503Cash conversion cycle ▼-7.173Capex / Sales ▲+0.078R&D / Sales ▲+0.006
Balance-sheet strength
Current ratio ▲+1.356Net debt / EBITDA ▲+0.009Working capital ▲+6100000.000Invested capital ▲+518000000.000Intangibles / Total assets -0.000
Change over 5 years
Valuation
Market cap ▲+122.5%EV / Sales ▲+10.6%EV / EBITDA ▼-15.4%EV / Op. cash flow ▼-3.207Earnings yield ▲+0.013Graham number ▲+184.536
Profitability
Return on equity ▲+0.068Return on assets ▲+0.077Return on invested capital ▲+0.070Return on capital employed ▲+0.093Operating ROA ▲+0.085Income quality ▼-0.088Tax burden ▼-0.022
Efficiency
Days sales outstanding ▼-2.867Days payables outstanding ▼-4.581Operating cycle ▼-108.494Cash conversion cycle ▼-103.913Capex / Sales ▲+0.092R&D / Sales ▼-0.148
Balance-sheet strength
Current ratio ▼-1.004Net debt / EBITDA ▼-0.707Working capital ▲+1123700000.000Invested capital ▲+2144400000.000Intangibles / Total assets ▲+0.006
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-06-11 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2023-05-12 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-05-12 | Michael McCaul | Sale | $100,001 - $250,000 |
| 2022-03-01 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2022-03-01 | Michael McCaul | Purchase | $1,001 - $15,000 |
| 2022-01-28 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2019-03-06 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-07-09 United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
- 2026-07-06 United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from currently approved products, providing a strong commercial base. Ralinepag and Nebulized Tyvaso in IPF are near-term pipeline catalysts, with multi-billion dollar peak sales potential if approved.
- 2026-07-06 United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.
- 2026-07-03 UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
- 2026-07-02 United Therapeutics Corporation Acquires Thymmune Therapeutics SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of th.
- 2026-07-01 14 value stocks of companies primed for rapid growth through 2028 Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.
- 2026-06-29 United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure that enables donor lungs to be assessed outside the body after procurement and before transplantation. The PMA, submitted by United Therapeutics' wholly.
- 2026-06-09 These 3 Stocks Lowered Their Share Counts Drastically in Q1 While markets often view large-scale buyback authorizations as positives in and of themselves, authorizations are just one part of the buyback equation. Unlike dividends, which companies must pay after declaring, there is no hard requirement for companies to spend the buyback capacity they authorize.
- 2026-06-05 Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report? United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
- 2026-06-04 SDZNY or UTHR: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?